Last reviewed · How we verify
NCT04907981
Eye Detection to Identify Novel Coronavirus Infection
trial testing Novel coronavirus infection in Covid19 in 232 participants. Completed in 26 April 2021.
26 April 2021
Quick facts
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 232 |
| Start date | 22 January 2021 |
| Primary completion | 26 April 2021 |
| Estimated completion | 26 April 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Novel coronavirus infection
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who can join
Under 75, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The eye characteristics of patients with COVID-19 and those without the disease were analyzed, and whether they had the disease or not was judged according to the eye characteristics.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Rapid COVID-19 Risk Screening by Eye-region Manifestations
Fu Y, Zhao L, Zheng H, Sun Q, et al · · 2021 -
Report on Three Round COVID-19 Risk Blind Tests by Screening Eye-region Manifestations
Fu Y, Zhao L, Zheng H, Sun Q, et al · · 2021 · DOI 10.1101/2021.06.23.21258626
Verify or expand the search:
- PubMed search for NCT04907981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
- NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
- NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04907981 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Last refreshed: 14 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing